Mr. Craig Schneider reports

INMED PHARMACEUTICALS STRENGTHENS SCIENTIFIC ADVISORY BOARD

InMed Pharmaceuticals Inc. has appointed Dr. Paul C. Anderson, PhD, to its scientific advisory board. Dr. Anderson is a pharma industry veteran who brings significant drug discovery and development expertise to InMed.

Dr. Anderson is a synthetic organic chemist by training with more than 30 years of experience in pharmaceutical research and development. Following postdoctoral studies in bioorganic chemistry at the University of Cambridge, Dr. Anderson began his career in the pharmaceutical industry at Merck Frosst Canada Inc. He subsequently joined Boehringer Ingelheim and, in more than 20 years with the company, held positions of increasing responsibility in the research organization including more than 12 years as head of the Boehringer Ingelheim research centres in Canada and in the United States. While in Canada, Dr. Anderson and his team introduced several anti-viral drugs into preclinical and clinical development, including the first HCV protease inhibitor to be tested in humans. As head of research for Boehringer Ingelheim in the United States, Dr. Anderson and his team carried out research on autoimmune and cardiovascular diseases, advancing several compounds into preclinical development. He received his PhD in organic chemistry at the University of Alberta.

Dr. Anderson is also a consultant for the National Institutes of Health (NIH) Blueprint Neurotherapeutics Network (BPN).

"We are delighted to have Paul join our scientific advisory board. Paul brings exceptional medicinal chemistry expertise and vast experience in drug discovery research in several therapeutic areas like CNS, immunology and inflammation and metabolic diseases," said Craig Schneider, president and chief executive officer of InMed.

In addition, InMed announced the appointment of Dr. Sazzad Hossain to its board of directors. Dr. Hossain is the current chief scientific officer of InMed and a co-founder of the company. He developed the IDP drug discovery platform and is leading all R&D activities of InMed Pharmaceuticals.

We seek Safe Harbor.